Emerging LVAD Technology for the Use - Washington Hospital Center

More documents

Recommendations

Info

HeartWare Ventricular Assist System Clinical Update at EACTS 2011 • 241 patients followed in ADVANCE and CAP with at least 6 months of follow up for 207 patient-years of support • Average duration of support: 313 days • Survival remains high at 92.7% at 180 days despite lower transplant rate than in prior BTT trials • Reoperations for bleeding as well as sepsis and driveline infections were infrequent • Focus on anti-platelet reduced thrombus events without increasing bleeding • Overall, adverse event rates remain low despite prolonged exposure to device support with improving survival and lower transplant rates
• GLP animal studies completed HeartWare MVAD • MVAD CE Mark study planned for 1H12, with 50 patients at 6-8 clinical sites • US IDE to commence after initial CE Mark patients are implanted
Page 1 and 2: Emerging LVAD Technologies for the
Page 3 and 4: Continuous Flow LVADs • Thoratec
Page 5 and 6: • Electrically powered • Percut
Page 7 and 8: • FDA approved Thoratec HeartMate
Page 9 and 10: Thoratec HeartMate III • Full-mag
Page 11 and 12: *In development and not available f
Page 13 and 14: HeartWare Ventricular Assist System
Page 17 and 18: Sintered HVAD Inlet
Page 19 and 20: HeartWare MVAD • Wide blade impel
Page 21 and 22: HeartWare MVAD Trans-Mitral “MVAD
Page 23 and 24: • Intraventricular axial flow pum
Page 25 and 26: Future applications • Total Ventr
Page 27 and 28: MicroMed HeartAssist 5 ® VAD Heart
Page 29: CircuLite ® Synergy ® Micro-Pump
Page 33 and 34: Potential VAD Patient Opportunity U
Page 35: Are We Ready?
Page 41: Fully-Implantable System: Energy Tr

Emerging LVAD Technology for the Use - Washington Hospital Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?